Ophthalmic Drugs Research Study by Prescription(Prescription Ophthalmic Drugs, Over-the-counter (OTC) Drugs), by Therapeutics(Glaucoma Ophthalmic Drugs, Retinal Disorder Ophthalmic Drugs, Dry Eye Ophthalmic Drugs, Allergic Conjunctivitis), by Region: Market Size, Share, Growth & Forecast to 2027

Publisher: GB Market Research | Published on: 09 Jan 2021| Category: Pharmaceuticals| Pages: 102

The global ophthalmic drugs market size is accounted for aroud USD 30 billion in 2019 and projected to grow at the CAGR of 5.9% market during the forecast period 2020-2027. Globally, the average life expectancy has been increasing and its posturing medical issues within the ophthalmology field are being strongly reflected. Among the elderly population, loss of eyesight is a major health problem. Growing prevalence of eye disorders has created a huge market for ophthalmic drugs. Moreover, new technologies combining drugs and device therapies are contributing significantly towards the development of ophthalmic drugs market.

Market Insights:

The key factors responsible for the growth of drug market are aging population and rising prevalence of ophthalmic disorders. In the base year 2016, prescription ophthalmic drugs are anticipated to hold the largest revenue share in the ophthalmic drugs market due to increasing number of patients suffering from various new retinal disorders and complicated cases of glaucoma and cataract. Glaucoma ophthalmic drugs held the largest share in therapeutic market segment due to large patient pool suffering with ophthalmic disorders, early diagnosis and treatment. The ophthalmic drugs market is currently dominated by North America due to increasing prevalence of ophthalmic disorders, favorable reimbursement scenario and developed healthcare infrastructure. Asia Pacific will be the fastest growing market due to aging population, large number of ophthalmic surgeries performed and rapid development in the healthcare infrastructure.

Market Segment Insights:

The global ophthalmic drugs market is segmented by prescription type such as (prescription ophthalmic drugs, and over-the-counter drugs). Prescription ophthalmic drugs segment is anticipated to hold the largest market in the ophthalmic drugs market during the forecast period. The prime factor that would determine the growth of prescription drugs segment include the increasing number of patients suffering from various new retinal disorders and complicated cases of glaucoma and cataract. Moreover, increasing rate of success for newly launched drugs which can only be bought by prescriptions would further assist the market growth. The therapeutic segment consists of (glaucoma ophthalmic drugs, retinal disorder ophthalmic drugs, dry eye ophthalmic drugs and allergic conjunctivitis). Glaucoma ophthalmic drugs held the largest share in global ophthalmic drugs market due to large patient pool suffering with ophthalmic disorders, early diagnosis and treatment.

Global Ophthalmic Drugs Market Segmentation:

By Prescription, 2018–2027 ($ Million)

  • Prescription Ophthalmic Drugs
  • Over-the-counter (OTC) Drugs

By Therapeutics, 2018–2027 ($ Million)

  • Glaucoma Ophthalmic Drugs
  • Retinal Disorder Ophthalmic Drugs
  • Dry Eye Ophthalmic Drugs
  • Allergic Conjunctivitis   

By Geography, 2018-2027 ($ Million)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Regional Insights:

North America, Latin America, Europe, Middle East and Africa and Asia Pacific, markets together form the major regional markets for ophthalmic drugs products. These regional markets are further sub-segmented into country specific markets on the basis of demand and market growth of ophthalmic drugs market. Among the considered regional markets, North America currently dominates the global ophthalmic drugs market, with United States being the largest county-level market. The drivers for North America market are significant patient pool, early disease diagnosis and treatment, and favorable reimbursement policies. Additionally, Asia Pacific is anticipated to be the fastest growing market for geriatric population, rising investments in healthcare infrastructure and increasing prevalence of ocular diseases, which includes disorders of both the cornea and the retina.

Market Competition Assessment:

The major players currently operating in the global ophthalmic drugs market include Abbott healthcare, Allergan plc, Johnson and Johnson, Bayer, Valeant pharmaceuticals, Inc. Akorn, Renegeron, Eyemed, Senju pharmaceutical Co.ltd., Pfizer, Inc., Merck and Co., Novartis AG, Glaxosmithkline, Eyegate pharmaceuticals, LPath, Senten pharmaceuticals Co. Ltd., Cipla pharmaceuticals, Sun pharmaceutical industries, Ltd. and other notable players.

List of Key Companies:

  • Abbott Healthcare
  • Allergan Plc
  • Akorn
  • Bayer Johnson & Johnson
  • Cipla Pharmaceuticals Bayer
  • Eyemed
  • Eyegate Pharmaceuticals
  • Johnson & Johnson
  • LPath
  • Merck & Co.
  • Novartis AG
  • Pfizer, Inc.
  • Senju Pharmaceutical Co., Ltd
  • Senten Pharmaceutical Co. Ltd
  • Sun Pharmaceutical Industries, Ltd.
  • Valeant Pharmaceuticals, Inc. 

Chapter 1 Methodology and Scope

1.1 Research Methodology

1.2 Research Scope & Assumptions

1.3 List and Data Sources

 

Chapter 2 Executive Summary

2.1 Global Ophthalmic Drugs Market - Industry Summary & Key Buying Criteria

2.2 Global Ophthalmic Drugs Market - Industry Outlook

 

Chapter 3 Global Ophthalmic Drugs Market Dynamics

3.1 Market Driver Analysis

3.1.1 Global rise in geriatric population pushing ophthalmology drugs

3.1.2 Technology advancement

3.1.3 Innovation giving rise to ophthalmology drugs market

3.1.4 Global increase in prevalence of eye diseases

3.1.5 Global increase in healthcare expenditure

3.2 Market Restrains Analysis

3.2.1 Major drugs going off patent is affecting the growth of ophthalmology market

3.2.2 Drying pipelines is a concern for major players

3.3 Key Opportunities Prioritized

3.3.1 Increasing awareness

3.3.2 Emerging markets

3.4 Global Ophthalmic Drugs Industry Value Chain Analysis

3.5 Attractive Investment Proposition

3.6 Market Competition Assessment, by Key Players: Global ophthalmic drugs market

 

 

Chapter 4 Global Ophthalmic Drugs Market, by Prescription Type, 2018-2027 ($ Million)

4.1 Global Prescription Market for Ophthalmic Drugs, 2018-2027 ($ Million)

4.2 Global OTC (Over the Counter) Drugs Ophthalmic Drugs Market 2018-2027 ($ Million)

 

Chapter 5 Global Ophthalmic Drugs Market, by Therapeutic Type, 2018-2027 ($ Million)

5.1 Global Glaucoma Ophthalmic Drugs, 2018-2027 ($ Million)

5.2 Global Retinal Disorder Ophthalmic Drugs Market 2018-2027 ($ Million)

5.3 Global Dry Eye Ophthalmic Drugs Market, 2018-2027 ($ Million)

5.4 Global Allergic Conjunctivitis Ophthalmic Drugs Market 2018-2027 ($ Million)

 

Chapter 6 Global Wound Care Market, by Geography, 2018-2027 ($ Million)

6.1 Overview

6.2 North America

6.2.1. U.S.

6.2.2. Canada

6.3 Europe

6.3.1. U.K.

6.3.2. Germany

6.3.3 Rest of Europe

6.4 Asia Pacific

6.4.1. Japan

6.4.2. China

6.4.3. Rest of Asia Pacific

6.5 Latin America

6.5.1. Brazil

6.5.2. Mexico

6.5.3. Rest of Latin America

6.6 Middle East and Africa

6.6.1. GCC

6.6.2. Rest of Middle East and Africa

 

Chapter 7 Company Profiles

7.1 Abbott Healthcare

7.2 Allergan Plc

7.3 Akorn

7.4 Bayer Johnson & Johnson

7.5 Cipla Pharmaceuticals Bayer

7.6 Eyemed

7.7 Eyegate Pharmaceuticals

7.8 Johnson & Johnson

7.9 LPath

7.10 Merck & Co.

7.11 Novartis AG

7.12 Pfizer, Inc.

7.13 Senju Pharmaceutical Co., Ltd

7.14 Senten Pharmaceutical Co. Ltd

7.15 Sun Pharmaceutical Industries, Ltd.

7.16 Valeant Pharmaceuticals, Inc.

7.17 Other Notable Players

List of Tables List of Figures

List of Key Companies:

  • Abbott Healthcare
  • Allergan Plc
  • Akorn
  • Bayer Johnson & Johnson
  • Cipla Pharmaceuticals Bayer
  • Eyemed
  • Eyegate Pharmaceuticals
  • Johnson & Johnson
  • LPath
  • Merck & Co.
  • Novartis AG
  • Pfizer, Inc.
  • Senju Pharmaceutical Co., Ltd
  • Senten Pharmaceutical Co. Ltd
  • Sun Pharmaceutical Industries, Ltd.
  • Valeant Pharmaceuticals, Inc. 
Select License Type
Single User: $3600
Multi User: $4800
Corporate User: $6800
Why To Choose Us:
  • Our expert team will assist you with all research need and customization
  • Our expert research analysts will resolve your every query before and after purchasing the report
  • We focus on the accuracy and quality of the report
  • Our analyst will provide deep insights into the report
  • Markets in over 150 countries analyzed granularly
  • 35% of our total client base has an annual subscription membership
  • 24x7 availability – we are always there when you need us
  • 100,000+ data points in our comprehensive database
For Any Assitance
Call Us: +91 9893685690
Contact Person: Mr. Vijendra Singh
Contact Email: sales@gbmarketresearch.com